Effectiveness of an antenatal maternal supplementation with prebiotics for preventing atopic dermatitis in high-risk children (the PREGRALL study): protocol for a randomised controlled trial

Clémentine Cabridain, Hélène Aubert, Bertrand Kaeffer, Virginie Badon, Marion Boivin, Vincent Dochez, Norbert Winer, Elodie Faurel-Paul, Lucie Planche, David Riochet, Annabel Maruani, Franck Perrotin, Catherine Droitcourt, Linda Lassel, Martine Tching-Sin, Natasha K Rogers, Marie Bodinier, Sebastien Barbarot, Clémentine Cabridain, Hélène Aubert, Bertrand Kaeffer, Virginie Badon, Marion Boivin, Vincent Dochez, Norbert Winer, Elodie Faurel-Paul, Lucie Planche, David Riochet, Annabel Maruani, Franck Perrotin, Catherine Droitcourt, Linda Lassel, Martine Tching-Sin, Natasha K Rogers, Marie Bodinier, Sebastien Barbarot

Abstract

Introduction: Atopic dermatitis (AD) is a chronic inflammatory disease affecting 10%-15% of children in Europe. There is a need for new primary preventive therapeutic strategies in at-risk populations. Recent research has indicated that atopic diseases are associated with a disrupted gut microbial 'balance' in early life raising the possibility that interventions which yield optimal patterns of microflora could improve host's health. Prebiotics, sugars with immunomodulatory properties that stimulate the diversity of the digestive microbiota, are ideal candidates for such research. So far, most clinical trials have focused on improving infant gut colonisation postnatally. However, prenatal life is a crucial period during which different tolerance mechanisms are put in place. We aim to determine whether antenatal prebiotics supplementation prevents AD in high-risk children.

Methods and analysis: This is a randomised, multicentre, double-blind, trial to evaluate the effectiveness of antenatal prebiotic maternal supplementation (galacto-oligosaccharide/inulin) in pregnant women versus placebo on the occurrence of AD at 1 year of age in at-risk children (defined as having a maternal history of atopic disease). Participating women will be randomised to daily ingestion of a prebiotics or placebo (maltodextrin) from 20 weeks' gestation until delivery. The primary outcome is the prevalence of AD at 1 year of age, using the version of the UK Working Party Diagnostic Criteria optimised for preventive studies. Key secondary endpoints are AD severity, quality of life and prebiotics tolerance. The target sample size is 376 women (188 patients per group) which will provide 80% power to detect a 33% reduction of the risk of AD in the verum group (α=0.05). The primary analysis will be based on the intention-to-treat principle.

Ethics and dissemination: Results will be presented in peer-reviewed journals and at international conferences. Ethics approval for the study was obtained from the institutional ethical review board of 'Comité de Protection des Personnes Sud Ouest-Outre-Mer III' of the University Hospital Centre of Bordeaux (2017/13).

Trial registration number: NCT03183440; Pre-results.

Keywords: dermatology; eczema; paediatric dermatology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Participant flow diagram. 1Timepoints ± 6 days; 2timepoint ± 7 days; 3blood, stool and DNA; 4stool and DNA. CIMMAP, Characterising the effect of maternal prebiotic supplementation on perinatal Immune system maturation, Microbiota and breast Milk compositions for Allergy Prevention in high-risk children; FDLQI, Family Dermatitis Quality of Life Index; ISAAC, International Study of Asthma and Allergies in Childhood; POEM, Patient-Oriented Eczema Measure; SCORAD, Scoring Atopic Dermatitis; TEWL, transepidermal water loss.
Figure 2
Figure 2
Participant flow in the feasibility study. CIMMAP, Characterising the effect of maternal prebiotic supplementation on perinatal Immune system maturation, Microbiota and breast Milk compositions for Allergy Prevention in high-risk children.

References

    1. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J 2014;7:1–3. 10.1186/1939-4551-7-12
    1. DaVeiga SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc 2012;33:227–34. 10.2500/aap.2012.33.3569
    1. Weidinger S, Beck LA, Bieber T, et al. . Atopic dermatitis. Nat Rev Dis Primers 2018;4:1):1 10.1038/s41572-018-0001-z
    1. Nylund L, Nermes M, Isolauri E, et al. . Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. Allergy 2015;70:241–4. 10.1111/all.12549
    1. Werfel T, Allam JP, Biedermann T, et al. . Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016;138:336–49. 10.1016/j.jaci.2016.06.010
    1. Pfefferle PI, Büchele G, Blümer N, et al. . Cord blood cytokines are modulated by maternal farming activities and consumption of farm dairy products during pregnancy: the PASTURE Study. J Allergy Clin Immunol 2010;125 108–15. 10.1016/j.jaci.2009.09.019
    1. Jiménez E, Fernández L, Marín ML, et al. . Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr Microbiol 2005;51:270–4. 10.1007/s00284-005-0020-3
    1. Gourbeyre P, Desbuards N, Grémy G, et al. . Exposure to a galactooligosaccharides/inulin prebiotic mix at different developmental time points differentially modulates immune responses in mice. J Agric Food Chem 2012;60:11942–51. 10.1021/jf3036403
    1. Gourbeyre P, Desbuards N, Grémy G, et al. . Perinatal and postweaning exposure to galactooligosaccharides/inulin prebiotics induced biomarkers linked to tolerance mechanism in a mouse model of strong allergic sensitization. J Agric Food Chem 2013;61:6311–20. 10.1021/jf305315g
    1. Bouchaud G, Castan L, Chesné J, et al. . Maternal exposure to GOS/inulin mixture prevents food allergies and promotes tolerance in offspring in mice. Allergy 2016;71:68–76. 10.1111/all.12777
    1. Fujiwara R, Takemura N, Watanabe J, et al. . Maternal consumption of fructo-oligosaccharide diminishes the severity of skin inflammation in offspring of NC/Nga mice. Br J Nutr 2010;103 530–8. 10.1017/S000711450999198X
    1. Hogenkamp A, Thijssen S, van Vlies N, et al. . Supplementing pregnant mice with a specific mixture of nondigestible oligosaccharides reduces symptoms of allergic asthma in male offspring. J Nutr 2015;145 640–6. 10.3945/jn.114.197707
    1. Grüber C, van Stuijvenberg M, Mosca F, et al. . Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants. J Allergy Clin Immunol 2010;126:791–7. 10.1016/j.jaci.2010.07.022
    1. Grüber C, van Stuivenberg M, Mosca F, et al. . Immunoactive prebiotics transiently prevent occurrence of early atopic dermatitis among low-atopy-risk infants. J Allergy Clin Immunol 2015;136:1696–8. 10.1016/j.jaci.2015.07.049
    1. Cuello-Garcia C, Fiocchi A, Pawankar R, et al. . Prebiotics for the prevention of allergies: A systematic review and meta-analysis of randomized controlled trials. Clin Exp Allergy 2017;47:1468–77. 10.1111/cea.13042
    1. Osborn DA, Sinn JKH. Cochrane Neonatal Group. Prebiotics in infants for prevention of allergy. Cochrane Database Syst Rev 2013;126:Cd006474 10.1002/14651858.CD006474.pub3
    1. Pedersen A, Sandström B, Van Amelsvoort JM. The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. Br J Nutr 1997;78:215–22. 10.1079/BJN19970141
    1. Simpson EL, Keck LE, Chalmers JR, et al. . How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. J Allergy Clin Immunol 2012;130:137–44. 10.1016/j.jaci.2012.01.075
    1. Asher MI, Keil U, Anderson HR, et al. . International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J 1995;8:483–91. 10.1183/09031936.95.08030483
    1. Kunz B, Oranje AP, Labrèze L, et al. . Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10–19. 10.1159/000245677
    1. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004;140:1513–9. 10.1001/archderm.140.12.1513
    1. Basra MK, Sue-Ho R, Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol 2007;156:528–38. 10.1111/j.1365-2133.2006.07617.x
    1. Heinzerling L, Mari A, Bergmann KC, et al. . The skin prick test - European standards. Clin Transl Allergy 2013;3:3 10.1186/2045-7022-3-3
    1. Wadonda-Kabondo N, Sterne JA, Golding J, et al. . Association of parental eczema, hayfever, and asthma with atopic dermatitis in infancy: birth cohort study. Arch Dis Child 2004;89 917–21. 10.1136/adc.2003.034033

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅